Legha S S, Slavik M, Carter S K
Cancer. 1976 Jul;38(1):27-35. doi: 10.1002/1097-0142(197607)38:1<27::aid-cncr2820380106>3.0.co;2-n.
Hexamethylmelamine (HMM) has been undergoing clinical trials for about a decade under the sponsorship of the National Cancer Institute. It has been tested in Phase II and III cooperative group studies and has a wide spectrum of activity in solid tumors. Its activity is most marked in ovarian cancer, lymphomas, and carcinoma of the cervix; the drug is also active in bronchogenic carcinoma and carcinoma of the breast. Considerable clinical evidence suggests a lack of cross-resistance between HMM and alkylating agents. the currently popular dose is 300 mg/m2/day p.o. for indefinite periods if tolerated. The dose-limiting toxicity is neurologic, but gastrointestinal side effects and a moderate degree of myelosuppression are also observed. Combination chemotherapy using HMM is underway in ovarian and lung cancer. Futher exploration of its activity as a single agent in tumors such as those of the bladder, prostate, and uterus, and in combination chemotherapy in lymphomas, and mammary, cervical, and pulmonary tumors is warranted.
在国家癌症研究所的赞助下，六甲蜜胺（HMM）已经历了大约十年的临床试验。它已在II期和III期合作组研究中进行了测试，并且在实体瘤中具有广泛的活性。其活性在卵巢癌、淋巴瘤和宫颈癌中最为显著；该药物在支气管癌和乳腺癌中也有活性。大量临床证据表明，HMM与烷化剂之间不存在交叉耐药性。如果耐受，目前常用的剂量是口服300mg/m²/天，持续不定时间。剂量限制性毒性是神经毒性，但也观察到胃肠道副作用和中度骨髓抑制。使用HMM的联合化疗正在卵巢癌和肺癌中进行。有必要进一步探索其作为单一药物在膀胱癌、前列腺癌和子宫癌等肿瘤中的活性，以及在淋巴瘤、乳腺癌、宫颈癌和肺癌中的联合化疗活性。
